- In TKI-naïve ROS1+ Patients, Overall Response Rate by Blinded Review is 82 Percent, and 83 Percent at Likely Recommended Phase 2 Dose of 160 mg QD or Above; Median Duration of Response across all Dose Levels Not Yet Reached
- Since Prior Update, Overall Response Rate by Blinded Review Increased in ROS1+ Patients Pretreated with one Prior TKI to 39 percent and to 55 Percent at Doses of 160 mg QD or Above
- All Five ROS1+ Crizotinib-Pretreated Patients with G2032R Solvent Front Mutation had Tumor Regressions, and Overall Response Rate by Blinded Review is 40 Percent
- Phase 2 Portion of TRIDENT-1 Registrational Study on Track for Initiation in 2H 2019
- Company Files 10-Q and Provides Financial Update
Friday, May 31, 2019
Turning Point Therapeutics Updates Lung Cancer Data
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.